Ketamine for depression: all studies (page 55)

Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: Findings from a 32-week randomised, open-label, rater-blinded phase IIIb study.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology April 1, 2025 Eduard Vieta, Nahida Ahmed, Celso Arango et al. 12 citations

Patients with treatment resistant depression (TRD) experience a greater negative impact on their functioning and productivity at home and in the workplace versus treatment-responsive patients. Here, we report the effects of esketamine nasal spray (NS) versus quetiapine extended release (XR) on functioning, work productivity and activity impairment. ESCAPE‑TRD (NCT04338321) was a 32-week...

DOI: 10.1016/j.euroneuro.2024.12.013 Full text Esketamine Major depressive disorder Treatment-resistant depression Functioning and productivity +7

Oral ketamine for rapid reduction of suicidal ideation in major depressive disorder: A midazolam-controlled randomized clinical trial.

Asian Journal of Psychiatry April 1, 2025 Asif Seraj, Mohammed Reyazuddin, R K Gaur et al. 11 citations

The simplest, most convenient, and least expensive way to treat depressed and suicidal patients with ketamine is to administer racemic ketamine by the oral route. We describe the first active-controlled randomized clinical trial of oral racemic ketamine for suicidal ideation associated with depression. Adult patients with major depressive disorder and expressed suicidal ideation were randomized...

DOI: 10.1016/j.ajp.2025.104413 Full text Major depressive disorder Adverse effects Midazolam Oral ketamine +7

Increased sensitivity to psychomotor effects of ketamine enantiomers in the Wistar-Kyoto depression model.

Journal of Psychiatric Research April 1, 2025 Kristian Elersič, Anamarija Banjac, Marko Živin et al. 3 citations

Ketamine, a fast-acting antidepressant, is a racemic mixture, composed of equal amounts of R- and S-ketamine. Preclinical studies are comparing them to better understand their role in therapeutic and undesirable effects. An important research gap is that studies do not use long clinically relevant protocols to compare the desired and undesired effects of ketamine enantiomers in modeled and...

DOI: 10.1016/j.jpsychires.2025.02.061 Full text Depressive disorder Depression mood disorder Clinical depression Ketamine ketalar +10

Effect of esketamine on postoperative depression in women with breast cancer and preoperative depressive symptoms: The EASE randomized trial.

Journal of clinical anesthesia April 1, 2025 Qingfeng Wei, Mengmeng Li, Qiuling Du et al. 10 citations

To determine whether intraoperative low-dose esketamine ameliorates depression in women having breast cancer surgery. A prospective single-center double blind randomized placebo-controlled trial. Perioperative period, operating room, post anesthesia care unit and hospital ward. 108 women 18-65 years old who were scheduled for elective breast cancer surgery. All had preoperative depressive...

DOI: 10.1016/j.jclinane.2025.111821 Full text Depression Anti-depressant Breast cancer Surgery +5

Ketamine Versus Electroconvulsive Therapy for the Treatment of Depression: A Guide for Clinicians.

Focus (American Psychiatric Publishing) April 1, 2025 Sophie I Elliott, Rachel B. Katz, Robert Ostroff et al. 2 citations

The effective treatment of major depressive disorder remains one of the biggest public health challenges globally. For moderate to severe cases, pharmacotherapy often falls short, leading to treatment-resistant depression. Electroconvulsive therapy (ECT) has generally been considered the gold standard for severe cases of treatment-resistant depression. However, emerging evidence suggests that...

DOI: 10.1176/appi.focus.20240040 Full text Major depressive disorder Patient-centered Electroconvulsive therapy ect Shock therapy +5

Ketamine-Assisted Psychotherapy for Treatment of Co-occurring Borderline Personality Disorder and Depression: A Case Study.

Journal of personality disorders April 1, 2025 Albert Yeung, Michael Alpert, David Mischoulon 3 citations

Borderline personality disorder (BPD) is a mental health condition characterized by a pervasive pattern of impulsivity, affective dysregulation, and cognitive-perceptual symptoms. Treatment of BPD remains a significant challenge to mental health clinicians. People who suffer from BPD frequently have comorbid psychiatric disorders, which makes treatment more complex. This case study describes a...

DOI: 10.1521/pedi.2025.39.2.170 Full text Major depressive disorder Psychedelic-assisted psychotherapy Treatment-resistant depression Psychedelic therapy +3

Neuropharmacology of Ketamine and Its Use in the Treatment of Major Depressive Disorder: A Review.

Cureus April 1, 2025 Zach Papadopoulos 1 citation

Depression is a common yet potentially debilitating mood disorder with complex neurobiological underpinnings, including deficiencies in monoaminergic and glutamatergic signaling, overactivity of the lateral habenula, and dysregulation of brain-derived neurotrophic factor (BDNF) signaling. Ketamine has emerged as a mechanistically novel, effective, and rapidly acting antidepressant. Ketamine's...

DOI: 10.7759/cureus.83244 Full text Major depressive disorder Synaptic plasticity Treatment-resistant depression Bdnf-trkb signaling +6

Comparative Efficacy and Functional Outcomes of Psychedelic-Assisted Therapies in Treatment-Resistant Depression: A Systematic Review of Recent Clinical Trials.

Cureus April 1, 2025 Ciara Mimms, Kassandra Sotelo, Abdul Saboor Khaliq 1 citation

This systematic review explores the comparative efficacy and functional outcomes of psychedelic-assisted therapies in the management of treatment-resistant depression (TRD). Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a comprehensive literature search was conducted across PubMed, Scopus, and Web of Science for randomized controlled...

DOI: 10.7759/cureus.82532 Full text Ketamine Psilocybin Psychedelic-assisted therapy Antidepressant response +10

Innovative approaches in the treatment-resistant depression: exploring different therapeutic pathways.

GeroScience March 25, 2025 Anna Łysik, Katarzyna Logoń, Aleksandra Szczygieł et al. 8 citations

Treatment-resistant depression (TRD) remains a vital challenge in psychiatry, affecting a significant number of patients with major depressive disorder. Current pharmacological approaches often do not provide sufficient therapeutic results, prompting the need for innovative treatments. This review summarizes recent advances in TRD management, including non-pharmacological therapies such as...

DOI: 10.1007/s11357-025-01615-8 Full text Ketamine Treatment-resistant depression Deep brain stimulation Electroconvulsive therapy +6

Monoamine neurotransmitter-related gene-based genome-wide association study of low-dose ketamine in patients with treatment-resistant depression.

Journal of psychopharmacology (Oxford, England) March 24, 2025 Chung-Feng Kao, Shih-Jen Tsai, Tung-Ping Su et al. 1 citation

Low-dose ketamine is an N-methyl-D-aspartate receptor antagonist that exerts an antidepressant effect on patients with treatment-resistant depression (TRD). This antidepressant effect may extend beyond the glutamatergic hypothesis. Nevertheless, the roles of genes encoding other monoamine neurotransmitters (i.e., serotonin and dopamine) in the neuromechanism of low-dose ketamine remain unknown....

DOI: 10.1177/02698811251326939 Full text Treatment-resistant depression Neurotransmitter studies Psychiatric genomics Antidepressant mechanisms +4